Geninus

Geninus Equity

The The Equity of Geninus (389030.KQ) as of Oct 24, 2026 is 9.10 B KRW. In the previous year, The Equity was 22.24 B KRW — a change of -59.07% (lower).

Equity

9.10 BKRW

YoY

-59.07%

Last updated:

In 2025, Geninus's equity was 9.10 B KRW, a -59.07% increase from the 22.24 B KRW equity in the previous year.

The Geninus Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
852.61 M KRW
Jan 1, 2019
-2.22 B KRW
Jan 1, 2020
-11.22 B KRW
Jan 1, 2021
51.91 B KRW
Jan 1, 2022
43.27 B KRW
Jan 1, 2023
34.49 B KRW
Jan 1, 2024
22.24 B KRW
Jan 1, 2025
9.10 B KRW
The Geninus Equity history
YEAREquityYoY
9.10 BKRW-59.07%
22.24 BKRW-35.52%
34.49 BKRW-20.30%
43.27 BKRW-16.64%
51.91 BKRW-562.46%
-11.22 BKRW+405.47%
-2.22 BKRW-360.44%
852.61 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Geninus Stock analysis

What does Geninus do? Geninus Inc. generates revenue through the provision of single cell analysis services and genetic testing for disease prediction to the public. The company develops and manufactures genome analysis solutions, including cancer genome analysis based on tissue biopsy, and offers personal genetic testing services. Additionally, Geninus Inc. engages in software development and a rental business as part of its product portfolio. The primary customers are individuals seeking genetic insights for health management and healthcare providers requiring advanced genomic analysis tools. The company's products include NGS-based genome analysis technology, cancer genome analysis solutions, and personal genetic testing services. These offerings target healthcare institutions, medical professionals, and consumers interested in personalized health assessments. Geninus Inc. also develops software for genomic data processing, which supports its service delivery and rental business model. Revenue streams are derived from direct sales of genome analysis solutions, service fees for single cell and cancer genome analysis, and subscriptions for software and rental services. The firm's focus on NGS technology positions it within the biotechnology sector, serving both clinical and consumer markets with a range of genomic services and products. Geninus is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Geninus's Equity

Geninus's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Geninus's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Geninus's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Geninus's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Geninus’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Geninus stock

The Equity of Geninus is 9.10 B KRW in 2025.

The Equity of Geninus changed from 22.24 B KRW to 9.10 B KRW, representing a -59.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Geninus since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Geninus historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Geninus

All Key Metrics — Geninus